Toxic	toxic	O	B_disease
hepatitis	hepatitis	O	S_disease
induced	induced	O	O
by	by	O	O
antithyroid	antithyroid	B_chemical	O
drugs	drugs	I_chemical	O
:	:	O	O
four	four	O	O
cases	cases	O	O
including	including	O	O
one	one	O	O
with	with	O	O
cross-reactivity	cross-reactivity	O	O
between	between	O	O
carbimazole	carbimazole	S_chemical	O
and	and	O	O
benzylthiouracil	benzylthiouracil	S_chemical	O
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
This	this	O	O
study	study	O	O
was	was	O	O
conducted	conducted	O	O
to	to	O	O
assess	assess	O	O
the	the	O	O
occurrence	occurrence	O	O
of	of	O	O
hepatic	hepatic	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
encountered	encountered	O	O
with	with	O	O
antithyroid	antithyroid	B_chemical	O
drugs	drugs	I_chemical	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
Retrospective	retrospective	O	O
review	review	O	O
of	of	O	O
medical	medical	O	O
records	records	O	O
of	of	O	O
236	236	O	O
patients	patients	O	O
with	with	O	O
hyperthyroidism	hyperthyroidism	O	S_disease
admitted	admitted	O	O
in	in	O	O
our	our	O	O
department	department	O	O
(	(	O	O
in-	in-	O	O
or	or	O	O
out-patients	out-patients	O	O
)	)	O	O
from	from	O	O
1986	1986	O	O
to	to	O	O
1992	1992	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Four	four	O	O
patients	patients	O	O
(	(	O	O
1.7	1.7	O	O
%	%	O	O
)	)	O	O
were	were	O	O
identified	identified	O	O
with	with	O	O
toxic	toxic	O	B_disease
hepatitis	hepatitis	O	S_disease
which	which	O	O
could	could	O	O
reasonably	reasonably	O	O
be	be	O	O
attributed	attributed	O	O
to	to	O	O
the	the	O	O
use	use	O	O
of	of	O	O
antithyroid	antithyroid	O	O
agent	agent	O	O
.	.	O	O

Two	two	O	O
patients	patients	O	O
had	had	O	O
a	a	O	O
cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
induced	induced	O	O
by	by	O	O
carbimazole	carbimazole	S_chemical	O
(	(	O	O
N	n	O	O
 	 	O	O
omercazole	omercazole	O	O
)	)	O	O
.	.	O	O

Two	two	O	O
others	others	O	O
had	had	O	O
a	a	O	O
mixed	mixed	O	O
(	(	O	O
cholestatic	cholestatic	O	S_disease
and	and	O	O
cytolytic	cytolytic	O	O
)	)	O	O
hepatitis	hepatitis	O	S_disease
following	following	O	O
carbimazole	carbimazole	S_chemical	O
.	.	O	O

One	one	O	O
of	of	O	O
the	the	O	O
latter	latter	O	O
two	two	O	O
patients	patients	O	O
further	further	O	O
experienced	experienced	O	O
a	a	O	O
cytolytic	cytolytic	O	O
hepatitis	hepatitis	O	S_disease
which	which	O	O
appeared	appeared	O	O
after	after	O	O
Benzylthiouracil	benzylthiouracil	S_chemical	O
(	(	O	O
Basd	basd	O	O
 	 	O	O
ne	ne	O	O
)	)	O	O
had	had	O	O
replaced	replaced	O	O
carbimazole	carbimazole	S_chemical	O
.	.	O	O

Biological	biological	O	O
features	features	O	O
of	of	O	O
hepatitis	hepatitis	O	S_disease
disappeared	disappeared	O	O
in	in	O	O
all	all	O	O
cases	cases	O	O
after	after	O	O
cessation	cessation	O	O
of	of	O	O
the	the	O	O
incriminated	incriminated	O	O
drug	drug	O	O
,	,	O	O
while	while	O	O
biliary	biliary	O	O
,	,	O	O
viral	viral	O	O
and	and	O	O
immunological	immunological	O	O
searches	searches	O	O
were	were	O	O
negative	negative	O	O
.	.	O	O

Only	only	O	O
2	2	O	O
patients	patients	O	O
of	of	O	O
our	our	O	O
retrospective	retrospective	O	O
study	study	O	O
experienced	experienced	O	O
a	a	O	O
mild	mild	O	O
or	or	O	O
severe	severe	O	O
neutropenia	neutropenia	O	S_disease
.	.	O	O

CONCLUSION	conclusion	O	O
:	:	O	O
Toxic	toxic	O	B_disease
hepatitis	hepatitis	O	S_disease
is	is	O	O
a	a	O	O
potential	potential	O	O
adverse	adverse	O	O
effect	effect	O	O
of	of	O	O
antithyroid	antithyroid	B_chemical	O
drugs	drugs	I_chemical	O
which	which	O	O
warrants	warrants	O	O
,	,	O	O
as	as	O	O
for	for	O	O
haematological	haematological	O	O
disturbances	disturbances	O	O
,	,	O	O
a	a	O	O
pre-therapeutic	pre-therapeutic	O	O
determination	determination	O	O
and	and	O	O
a	a	O	O
careful	careful	O	O
follow-up	follow-up	O	O
of	of	O	O
relevant	relevant	O	O
biological	biological	O	O
markers	markers	O	O
.	.	O	O

Moreover	moreover	O	O
,	,	O	O
hepatotoxicity	hepatotoxicity	O	S_disease
may	may	O	O
not	not	O	O
be	be	O	O
restricted	restricted	O	O
to	to	O	O
one	one	O	O
class	class	O	O
of	of	O	O
antithyroid	antithyroid	B_chemical	O
agents	agents	I_chemical	O
.	.	O	O

